Intraventricular injection of 192-IgG-SAP (192-Saporin) results in almost complete elimination of LNGFR (p75NTR)-positive cells in rat. 192-IgG-SAP is directed to a cell-surface antigen that is only expressed at high levels on neurons in the cholinergic basal forebrain (CBF). The antigen, p75NTR, is not expressed on the neighboring, non-cholinergic neurons. 192-IgG-SAP specifically eliminates cholinergic neurons of the basal forebrain, medial septum, diagonal band of Broca, nucleus basalis of Meynert, and Purkinje neurons of the cerebellum. It provides researchers with a powerful lesioning tool – more specific and effective than chemical, surgical or electrolytic lesioning. Permanent and selective removal of cholinergic forebrain neurons makes an important animal model for the study of behavior, neuronal loss (e.g. Alzheimer’s disease), plasticity of other systems in response to loss, replacement therapy, and drug effects and dependence.

To eliminate p75NTR-expressing cells in mouse, use mu p75-SAP (Cat. #IT-16). To eliminate p75NTR-expressing cells in other mammals, use ME20.4-SAP (Cat. #IT-15).

192-IgG-SAP specifically eliminates cells expressing p75NTR, also known as the low affinity nerve growth factor receptor.

To view protocol(s) for this and other products please visit: www.ATSbio.com/support/protocols

Advanced Targeting Solutions（ATS）是一家位于圣地亚哥的生物技术公司，致力于为科学研究和药物开发提供高质量的靶向试剂。ATS被称为“萨波林人”，最初致力于为神经科学研究界提供研究工具。多年来，这些工具已用于科学研究和药物开发的所有领域。公司目前的产品线包括针对性毒素，抗体和定制服务，旨在帮助科学家研究系统功能，细胞功能，疾病和病症。ATS率先将靶向结合物用于“分子手术”技术。这些产品包括针对胆碱能性前脑神经元，去甲肾上腺素能和肾上腺素能神经元，巨噬细胞和小胶质细胞的特定损伤剂，以及能侵袭所有神经元上表达的抗原决定簇的泛神经元剂。此外，ATS还出售“次级结合物”，使用户可以将自己的靶向剂转化为特定的细胞毒性工具，并筛选抗体进行内在化。ATS已商业化，并提供了由Douglas Lappi博士开发和完善的Saporin技术平台的访问权限。拉皮博士与医学博士Ronald Wiley合作。在他们的学术实验室中，以验证使用主要的皂素结合物192-IgG-SAP来建立阿尔茨海默氏病模型。丹妮丝·希金斯（Denise Higgins）将她的业务专长和国际销售/营销经验带到了团队中，并将继续致力于将这一创新技术带给全球科学家。